CALCITONIN FOR PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS

被引：3

作者：

BODY, JJ

机构：

[1] Bone Metabolism Unit and Supportive Care Clinic, Dept. of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels

来源：

CLINICAL RHEUMATOLOGY | 1995年 / 14卷

关键词：

CALCITONIN; OSTEOPOROSIS; MENOPAUSE; BONE; FRACTURE; BREAST; CANCER;

D O I：

10.1007/BF02210683

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Prolonged calcitonin administration (intramuscular, subcutaneous, or intranasal) can prevent postmenopausal trabecular bone loss. Nasal administration constitutes a particularly attractive option for women who cannot tolerate or benefit from estrogen replacement therapy. The optimal schedule of administration still has to be precised, but 100 U/day of nasal calcitonin, combined with calcium supplements, can currently be recommended. Interrupted regimens are maybe favourable. Calcitonin can also prevent further bone loss in established osteoporosis particularly if bone turnover is increased. The anti-fracture efficacy of calcitonin is suggested by different types of studies but has not been formally demonstrated. Lastly, its analgesic efficacy in cases of painful vertebral compression fractures has been demonstrated in controlled studies.

引用

页码：18 / 21

页数：4

共 22 条

[1]

Mazzuoli G.F., Passeri M., Gennari C., Minisola S., Antonelli R., Valtorta C., Palummeri E., Cervellin G.F., Gonnelli S., Francini G., Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study, Calcif Tissue Int, 38, pp. 3-8, (1986)

[2]

Mazzuoli G.F., Tabolli S., Bigi F., Valtorta C., Minisola S., Diacinti D., Scarnecchia L., Bianchi G., Piolini M., Dell'Acqua S., Effects of salmon calcitonin on the bone loss induced by ovariectomy, Calcif Tissue Int, 47, pp. 209-214, (1990)

[3]

Ringe J.D., Ergebnisse einer kontrollierten einjähringen Behandlung der primären Osteoporose mit Calcium und Lachscalcitonin, Dtsch Med Wschr, 115, pp. 1176-1182, (1990)

[4]

MacIntyre I., Stevenson J.C., Whitehead M.I., Wimalawansa S.J., Banks L.M., Healy M.J.R., Calcitonin for prevention of postmenopausal bone loss, Lancet, 1, pp. 900-902, (1988)

[5]

Gennari C., Chierichetti S.M., Bigazzi S., Fusi L., Gonelli S., Ferrara R., Zacchei F., Comparative effects on bone mincral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis, Curr Therap Res, 38, pp. 455-464, (1985)

[6]

Civitelli R., Gonelli S., Zacchei F., Rifazzi S., Vatimo A., Avioli L.V., Gennari C., Bone turnover in postmenopausal osteoporosis: effect of calcitonin treatment, J Clin Invest, 82, pp. 1268-1274, (1988)

[7]

Ljunghall S., Gardsell P., Johnell O., Larsson K., Lindh E., Obrant K., Sernbo I., Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study, Calcif Tissue Int, 49, pp. 17-19, (1991)

[8]

Reginster J.Y., Denis D., Albert A., Franchimont P., Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (i.m.) or placebo injection in normal subjects, Bone Miner, 2, pp. 133-140, (1987)

[9]

Overgaard K., Agnusdei D., Hansen M.A., Maioli E., Christiansen C., Gennari C., Dose-response bioactivity of salmon calcitonin in premenopausal and postmenopausal women, J Clin Endocrinol Metab, 72, pp. 344-349, (1991)

[10]

Reginster J.Y., Denis D., Albert A., Deroisy R., Lecart M.P., Fontaine M.A., Lambelin P., Franchimont P., 1-year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin, Lancet, 2, pp. 1481-1483, (1987)

← 1 2 3 →